Glimepiride Accord (Glimepiride)

Glimepiride Accord is indicated for the oral treatment of type 2 diabetes mellitus in adults, typically as part of a comprehensive diabetes management plan.

• Improves fasting and post‑prandial blood glucose levels when combined with diet and exercise.
• May be used as monotherapy in patients who have not achieved glycemic targets with lifestyle changes alone.
• Can be added to other oral antidiabetic agents such as metformin when combination therapy is required.
• May assist in reducing HbA1c levels over several weeks of consistent use.
• Is prescribed when clinicians aim to stimulate endogenous insulin secretion in patients with residual pancreatic beta‑cell function.

The safety profile of Glimepiride Accord includes a range of adverse effects that vary in frequency and severity.

Common

• Low blood sugar (hypoglycemia)
• Nausea or abdominal discomfort
• Headache
• Dizziness or light‑headedness
• Weight gain
• Fatigue

Serious

• Severe hypoglycemia leading to loss of consciousness
• Allergic reactions such as rash, itching, or swelling
• Hepatic dysfunction indicated by elevated liver enzymes
• Blood disorders like leukopenia or thrombocytopenia
• Cardiovascular events such as arrhythmia
• Pancreatitis symptoms (upper abdominal pain)

Before initiating Glimepiride Accord, healthcare providers should evaluate several clinical factors to minimize risks and ensure appropriate use.

• Assess renal and hepatic function, as impairment may alter drug clearance.
• Verify that the patient retains sufficient pancreatic beta‑cell activity to respond to sulfonylureas.
• Use caution in elderly patients due to increased susceptibility to hypoglycemia.
• Review any history of cardiovascular disease, especially if concomitant with other hypoglycemic agents.
• Avoid use during pregnancy or breastfeeding unless the benefit outweighs potential risks.
• Monitor blood glucose regularly after dose adjustments.
• Educate patients on recognizing and managing hypoglycemia symptoms.

Glimepiride Accord can interact with several medicines, affecting its glucose‑lowering effect or increasing the risk of adverse reactions.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels.
• MAO‑B inhibitors, which may potentiate hypoglycemic effects.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, as they may reduce glucose control.
• Antidepressants such as SSRIs, which have been reported to affect blood sugar regulation.
• Antifungal agents like itraconazole, requiring close glucose monitoring.